Quick Answer
Dare Bioscience, Inc. reported Cash and Equivalents of $24.71 million for fiscal year 2025.
Dare Bioscience, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $24.71M | +57.4% |
| 2024 | $15.70M | +49.8% |
| 2023 | $10.48M | -69.8% |
| 2022 | $34.67M | -32.9% |
| 2021 | $51.67M | +1006.6% |
| 2020 | $4.67M | -2.3% |
| 2019 | $4.78M | -29.8% |
| 2018 | $6.81M | -10.0% |
| 2017 | $7.56M | +16845.0% |
| 2016 | $44.6K | -79.7% |
| 2015 | $219.4K | -99.6% |
| 2014 | $51.17M | +832.5% |
| 2013 | $5.49M | -67.2% |
| 2012 | $16.71M | +8.9% |
| 2011 | $15.35M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.08M | +105.4% | +358.3% |
| June 30, 2025 | $5.04M | -69.3% | -51.3% |
| March 31, 2025 | $10.33M | +184.5% | -34.2% |
| December 31, 2024 | $15.70M | +49.8% | +39.8% |
| September 30, 2024 | $11.23M | -19.2% | -31.6% |
| June 30, 2024 | $16.41M | +23.2% | +352.1% |
| March 31, 2024 | $3.63M | -81.6% | -65.3% |
| December 31, 2023 | $10.48M | -69.8% | -24.6% |
- Dare Bioscience, Inc. showed an increase of +57.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Dare Bioscience, Inc.’s cash and equivalents has grown by 61.0% (from $15.35 million to $24.71 million).
- The most recent figure is from Dare Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: